600645.SH
Vcanbio Cell & Gene Engineering Corp., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 17.61
+3.89%Margins
Gross margin
70.2%
EBITDA margin
24.1%
EBIT margin
12.6%
Net margin
7.7%
FCF margin
17.5%
3.0%
Return on equity
2.1%
Return on assets
4.7%
Return on invested capital
0.27x
Asset turnover
CNY 295.4M
Cash from operations
—
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026